Integrating Binary Silva Classification and Tumor Size for Predicting Survival in Early-Stage HPV-Associated Endocervical Adenocarcinoma
Abstract Background The optimal risk stratification for early-stage human papillomavirus-associated endocervical adenocarcinoma (HPVA) lacking conventional major high-risk factors remains clinically challenging. This study aimed to evaluate the independent prognostic utility of the binary Silva classification in this specific population and to develop a validated progression-free survival (PFS) nomogram for individualized risk assessment. Methods We retrospectively evaluated 163 patients with FIGO 2018 stage IA2–IIA2 HPVA who underwent radical surgery and lacked major high-risk pathological factors (e.g., lymph node metastasis). Patients were categorized into low- and high-risk binary Silva groups based on morphological invasive patterns and lymphovascular space invasion (LVSI) status. Multivariable Cox proportional hazards regression was utilized to identify independent prognosticators. A predictive PFS nomogram was constructed and internally validated utilizing 1,000 patient-level bootstrap resamples to calculate optimism-corrected performance metrics. Results Over a median follow-up of 48 months (95% CI, 40–59), the high-risk binary Silva group (n = 82) exhibited significantly inferior PFS and overall survival compared with the low-risk group (n = 81; P < 0.001 and P = 0.0015, respectively). Multivariable analysis confirmed that high-risk binary Silva status (hazard ratio [HR], 4.37; 95% CI, 1.64–11.62; P = 0.003) and tumor size ≥ 2 cm (HR, 4.05; 95% CI, 1.57–10.42; P = 0.004) were robust independent adverse predictors for PFS. The resulting two-factor predictive nomogram demonstrated favorable internal validity, yielding an optimism-corrected concordance index (C-index) of 0.717. Conclusion The binary Silva classification serves as a powerful, independent prognostic stratifier for early-stage HPVA without major high-risk factors. By integrating binary Silva status with tumor size, our internally validated nomogram provides a quantitative, practical framework to refine postoperative risk assessment and potentially guide individualized adjuvant treatment strategies.
Authors
- Jiehui Li (ORCID: https://orcid.org/0009-0006-5020-3617)
- Yidan Gong
- Lili Hu (ORCID: https://orcid.org/0000-0002-3683-9954)
- Fan Mei
- Xue Tian (ORCID: https://orcid.org/0000-0003-3403-8464)
- Yanjun Du
- Linman Wang
- Fenghu Li
- Zhenglin Li
Institutions
- Guiyang Medical University (CN)
- Affiliated Hospital of Guizhou Medical University (CN)
Publication Details
- Journal
- Research Square
- Published
- 2026-11-16
- DOI
- https://doi.org/10.21203/rs.3.rs-11450518/v1
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- preprint